New glycemic targets for patients with diabetes from the Japan Diabetes Society

Diabetology International

Volumn 7, Issue 4, 2016, Pages 327-330

  Araki, Eiichi ^a   Haneda, Masakazu ^b   Kasuga, Masato ^c   Nishikawa, Takeshi ^a,d   Kondo, Tatsuya ^a   Ueki, Kohjiro ^c   Kadowaki, Takashi ^e  

^a KUMAMOTO UNIVERSITY   (Japan)

^b ASAHIKAWA MEDICAL COLLEGE   (Japan)

^c NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION KUMAMOTO MEDICAL CENTER   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

Author keywords

Diabetes mellitus; Glycemic target; HbA1c; Japan Diabetes Society (JDS); Kumamoto Declaration 2013

Indexed keywords

HEMOGLOBIN A1C;

DIABETES MELLITUS; DIET THERAPY; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; JAPAN; KINESIOTHERAPY; LIFESPAN; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

EID: 85001930585     PISSN: 21901678     EISSN: 21901686     Source Type: Journal    
DOI: 10.1007/s13340-016-0297-4     Document Type: Review

References (12)

1. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–17.
2. Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. Diabetes Care. 1999;22:920–4.
3. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.
4. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–53.
5. Gerstein HC, Miller ME, Byington BP, Action to control cardiovascular risk in Diabetes Study Group, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.
6. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203.
7. Ito C, Maeda R, Ishida S, et al. Correlation among fasting plasma glucose, two-hour plasma glucose levels in OGTT and HbA1c. Diabetes Res Clin Pract. 2000;50:225–30.
8. Yamamoto-Honda R, Kitazato H, Hashimoto S, et al. Distribution of blood glucose and the correlation between blood glucose and hemoglobin A1c levels in diabetic outpatients. Endocr J. 2008;55:913–23.
9. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.
10. The Diabetes Control and Complications Trial (DCCT) Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes. 1996;45:1289–98.
11. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.
12. Balkau B, Hu G, Qiao Q, DECODE Study Group; European Diabetes Epidemiology Group, et al. Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study. Diabetologia. 2004;47:2118–28.